Ratings by Guggenheim (Paul Jeng)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/21/2026 | Kazia Therapeutics | KZIA | New Coverage | Buy (N/A) |
0.00 (7.81) |
0% | Details | |
| 9/15/2026 | Nanobiotix S.A | NBTX | New Coverage | Buy (N/A) |
35.73 (29.36) |
-17.83% | Details | |
| 9/9/2026 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 7/14/2026 | Adagene Inc | ADAG | Maintain | Buy (Buy) |
|
Details | ||
| 4/28/2026 | Corbus Pharmaceuticals | CRBP | New Coverage | Buy (N/A) |
10.08 (4.05) |
-59.82% | Details | |
| 4/14/2026 | Ideaya Biosciences | IDYA | Maintain | Buy (N/A) |
|
Details | ||
| 4/6/2026 | Adagene Inc | ADAG | Maintain | Buy (N/A) |
|
Details | ||
| 11/24/2025 | Adagene Inc | ADAG | New Coverage | Buy (N/A) |
1.80 (2.41) |
33.89% | Details | |
| 11/18/2025 | Immatics | IMTX | Maintain | Buy (N/A) |
|
Details | ||
| 9/18/2025 | Immunocore Holdings | IMCR | New Coverage | Neutral (N/A) |
33.81 (30.98) |
-8.37% | Details | |
| 9/18/2025 | Immatics | IMTX | New Coverage | Buy (N/A) |
6.00 (7.31) |
21.83% | Details | |
| 9/18/2025 | Context Therapeutics | CNTX | New Coverage | Buy (N/A) |
0.85 (0.24) |
-71.76% | Details | |
| 9/17/2025 | Ideaya Biosciences | IDYA | New Coverage | Buy (N/A) |
24.72 (34.71) |
40.41% | Details | |
| 7/29/2020 | Artara Therapeutics Inc. | TARA | New Coverage | Buy (N/A) |
27.45 (2.33) |
-91.51% | Details |
